Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5992512 | 0.88 | SCD (0.32) | SCDRAB9AALDH1A1TSHRRECQL | |
| SCHEMBL1320408 | 0.78 | VHL (0.41) | SCDRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5379544 | 0.77 | SCD (0.46) | SCDRAB9AALDH1A1TSHRRIPK1 | |
| SCHEMBL1320181 | 0.74 | VHL (0.41) | SCDALDH1A1S1PR1S1PR3 | |
| SCHEMBL14198669 | 0.74 | SCD (0.49) | SCDRAB9AALDH1A1TSHRRIPK1 | |
| SCHEMBL5782512 | 0.72 | RAB9A (0.37) | RAB9AALDH1A1TSHRRECQLNPC1 | |
| SCHEMBL1979609 | 0.67 | — | — | |
| SCHEMBL5783147 | 0.67 | — | — | |
| SCHEMBL1012620 | 0.67 | S1PR3 (0.46) | RAB9ANPC1S1PR1S1PR3TDO2 | |
| SCHEMBL5786695 | 0.67 | HRH3 (0.51) | RAB9AALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | claimed |
| US-7220865-B2 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-05-22 | — | — | US | claimed |
| EP-1735288-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005095361-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050222149-A1 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | claimed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7220865-B2 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1735288-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005095361-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222149-A1 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | NPY1R, PARK7, IAPP | SCD 4791/4885RAB9A 568/4885ALDH1A1 1694/4885 |
| US-20050222149-A1 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | NPY1R, PSEN1, APP | SCD 4772/4885RAB9A 1449/4885ALDH1A1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.